RBC Capital Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $77
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with an Outperform rating and a price target of $77.

April 22, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has initiated coverage on Ultragenyx Pharmaceutical with an Outperform rating and a price target of $77.
Analyst ratings, especially from reputable firms like RBC Capital, can significantly influence investor sentiment and stock prices. An Outperform rating suggests that the analyst believes the stock will perform better than the market or its sector, potentially leading to an increase in stock price. The announcement of a specific price target provides a tangible goal that can further influence investor expectations and stock valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100